Dearborn Partners LLC lifted its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 10.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,705 shares of the exchange traded fund’s stock after acquiring an additional 265 shares during the period. Dearborn Partners LLC’s holdings in SPDR S&P Biotech ETF were worth $267,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also made changes to their positions in the company. Hartline Investment Corp lifted its stake in SPDR S&P Biotech ETF by 2.0% during the third quarter. Hartline Investment Corp now owns 5,502 shares of the exchange traded fund’s stock worth $544,000 after purchasing an additional 106 shares during the last quarter. Intellectus Partners LLC lifted its position in shares of SPDR S&P Biotech ETF by 1.0% during the 2nd quarter. Intellectus Partners LLC now owns 11,334 shares of the exchange traded fund’s stock worth $1,051,000 after buying an additional 113 shares during the last quarter. Pacific Center for Financial Services boosted its stake in SPDR S&P Biotech ETF by 2.8% in the first quarter. Pacific Center for Financial Services now owns 4,359 shares of the exchange traded fund’s stock valued at $414,000 after buying an additional 118 shares in the last quarter. Kingsview Wealth Management LLC grew its position in SPDR S&P Biotech ETF by 3.8% in the first quarter. Kingsview Wealth Management LLC now owns 3,495 shares of the exchange traded fund’s stock valued at $332,000 after acquiring an additional 127 shares during the last quarter. Finally, Denver Wealth Management Inc. raised its stake in SPDR S&P Biotech ETF by 0.9% during the third quarter. Denver Wealth Management Inc. now owns 14,779 shares of the exchange traded fund’s stock worth $1,460,000 after acquiring an additional 127 shares in the last quarter.
SPDR S&P Biotech ETF Price Performance
XBI stock opened at $91.88 on Friday. The stock has a market cap of $7.00 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 1 year low of $69.32 and a 1 year high of $105.47. The company has a 50 day simple moving average of $98.95 and a 200 day simple moving average of $96.03.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- MarketBeat Week in Review – 11/11 – 11/15
- What is the Dogs of the Dow Strategy? Overview and Examples
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- What is the FTSE 100 index?
- Top-Performing Non-Leveraged ETFs This Year
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.